Showing results (191-200 of 207) with videos related to
Sort By:
Pageof 21
Cancer|September 27, 2012
Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer NetworkRachel A Freedman, Melissa E Hughes, Rebecca A Ottesen, et al.The New England Journal of Medicine|July 15, 2011
Health care spending and quality in year 1 of the alternative quality contractZirui Song, Dana Gelb Safran, Bruce E Landon, et al.International Journal of Clinical and Experimental Medicine|June 12, 2015
Rare blood donors screening by multiplex PCR methods in Chinese Zhuang and Dong population and pedigree analysisWei Jiao, Xiangcheng Liao, Hailan Li, et al.Health Affairs (Project Hope)|July 13, 2012
The 'Alternative Quality Contract,' based on a global budget, lowered medical spending and improved qualityZirui Song, Dana Gelb Safran, Bruce E Landon, et al.Journal of Registry Management|May 20, 2016
Linking the National Health Interview Survey with the Florida Cancer Data System: A Pilot StudyLaura A McClure, Eric A Miller, Stacey L Tannenbaum, et al.Journal of Palliative Medicine|April 19, 2014
Physicians' propensity to discuss prognosis is associated with patients' awareness of prognosis for metastatic cancersPang-Hsiang Liu, Mary Beth Landrum, Jane C Weeks, et al.Cancer|January 25, 2012
A snapshot of smokers after lung and colorectal cancer diagnosisElyse R Park, Sandra J Japuntich, Nancy A Rigotti, et al.Frontiers in Pharmacology|March 30, 2026
Real-world pharmacovigilance and molecular mechanisms of fruquintinib: SRC and STAT3 as potential off-target mediators of proteinuriaDuogang Xu, Zhicheng Dai, Yulei He, et al.Journal of the American Academy of Child and Adolescent Psychiatry|March 3, 2009
National comorbidity survey replication adolescent supplement (NCS-A): III. Concordance of DSM-IV/CIDI diagnoses with clinical reassessmentsRonald C Kessler, Shelli Avenevoli, Jennifer Green, et al.Human Vaccines & Immunotherapeutics|July 17, 2025
Phase I open-label study of the respiratory syncytial virus monoclonal antibody clesrovimab: Safety and tolerability in healthy Chinese participantsYulei He, Fengli Zhao, Xiao Yang, et al.Pageof 21